Stock Ratings / Health Care / CAMP / forecast

VNDA (37) LFCR (51) ELDN (49) EVMN (43) ⌘ Pro Terminal →

CAMP4 Therapeutics Corporation (CAMP) 12-Month Stock Forecast & Price Target Cone

$3.90 +6.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.94

CAMP4 Therapeutics Corporation (CAMP) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $244.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.94 (+1.04%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CAMP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY CAMP SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (35% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 21% of 52W Range • RSI-14 at 58.9 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.77-15.9% Next Q

Q2 (-2Q)

Grade E$3.17+4.1% Next Q

Q3 (-1Q)

Grade E$3.30+18.2% Next Q

Current

Grade E$3.90-8.7% Hist 90D α

Trajectory: E (26) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CAMP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CAMP currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.89) and Max Pain ($4.10) forces dealer call-delta covering toward $8.14.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CAMP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CAMP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CAMP Position Size: $10,000

Shares at $3.90: 2564.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.71

$6,949

$-3,051 (-30.5%)

12M Consensus BaseTarget $3.48

$8,923

$-1,077 (-10.8%)

12M Bull Case BreakoutTarget $8.14

$20,872

+$10,872 (+108.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$4	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$8	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CAMP)

✓Walkthrough of CAMP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CAMP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.47%📐 HORIZONTAL RANGE

2026-10-30O $3.87H $4.01L $3.78C $3.90VOL 137.7K

RES: $6.81SUP: $2.81SMA50: $3.89SMA200: $4.22

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CAMP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CAMP Butterfly Map → + Track CAMP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CAMP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CAMP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CAMP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CAMP)

Health Care Rank #842 of 1016 ⚔️ VNDA vs CAMP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CAMP vs. VNDA, LFCR, ELDN, EVMN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CAMP4 Therapeutics Corporation (CAMP) ranks #842 by composite RQD confidence (34/100, grade E) and #552 by equity capitalization ($244.7M). Within this direct 5-issuer industry benchmark cohort, CAMP leads on earnings valuation at N/A trailing P/E, while CAMP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with CAMP at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CAMP ACTIVE CAMP4 Therapeutics Corporation	E	34/100	—	—	-35.0%	+6.85%	$244.7M	Benchmark Subject
VNDA Vanda Pharmaceuticals Inc.	D-	37/100	—	—	-35.0%	+1.25%	$244.9M	/vnda-vs-camp →
LFCR Lifecore Biomedical Inc.	D	51/100	—	—	—	+0.15%	$246.8M	/lfcr-vs-camp →
ELDN Eledon Pharmaceuticals Inc.	D	49/100	—	—	-35.0%	+10.15%	$247.0M	/eldn-vs-camp →
EVMN Evommune Inc.	D-	43/100	—	—	-35.0%	+7.92%	$247.1M	/evmn-vs-camp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001736730

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CAMP4 Therapeutics Corporation (CAMP) reported GAAP revenue of $3.5M (+436.5% vs. FY2024 revenue of $652.0K , and +899.4% cumulative change since FY2023) , GAAP net income of -$80.4M, operating cash flow of -$29.6M, and free cash flow of -$29.8M (+35.2% YoY). On the balance sheet, CAMP closed FY2025 with $117.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.5M	-$80.4M	-$29.6M	-$29.8M	$117.8M	—
FY2024 (FY)	2024-12-31	$652.0K	-$51.8M	-$45.6M	-$46.0M	$78.3M	—
FY2023 (FY)	2023-12-31	$350.0K	-$49.3M	-$44.2M	-$44.2M	—	—

3. CAMP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CAMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CAMP4 Therapeutics Corporation (NASDAQ: CAMP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.90 (+6.85% 1D, market cap $244.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CAMP ranks #842 in composite RQD confidence.

How does CAMP compare to VNDA and LFCR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CAMP carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VNDA (Vanda Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $244.9M) and LFCR (Lifecore Biomedical Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $246.8M). Among the 5-stock peer group, CAMP leads on earnings multiple (N/A) while CAMP leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CAMP?

Per CAMP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001736730), CAMP4 Therapeutics Corporation generated $3.5M in revenue (+436.5% YoY), -$80.4M in net income, and -$29.8M in free cash flow against $117.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CAMP trading relative to its 50-day, 200-day, and 52-week technical levels?

CAMP last traded at $3.90 (+6.85% on volume of 151,983 shares), positioning the stock +0.26% above its 50-day simple moving average ($3.89) and -7.58% below its 200-day simple moving average ($4.22). Across its 52-week range of $2.90 to $7.75, CAMP sits at the 20.6% percentile with a 14-day RSI of 58.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($3.41 to $4.39).

CAMP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CAMP's 12-month stock price target?

CAMP4 Therapeutics Corporation (CAMP) carries a 12-month consensus base price target of $3.48 (-10.8% from $3.90), with a bull-case target of $8.14 and a bear-case floor of $2.71.

Is CAMP stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates CAMP E (Strong Sell — SELL) with an RQD Confidence score of 34/100.

Direct Sub-Reports: CAMP RQD Cockpit CAMP 12M Forecast CAMP Earnings & Move CAMP Dividends & DRIP CAMP Insiders & 13F CAMP Whale Options CAMP Profit Sankey CAMP News & Why